How oft is the Lu-PSMA treatment conducted? The usual cycle consists of 3 sessions with 6 to 8 weeks interval in-between. Our more restrictive treatment regimen of initial 3 cycles with an interval of only 4 weeks in-between demonstrated >80% response rates even in heavily pre-treated patients. This treatment does not care, “where” the metastases are: lymph nodes, bone,…

Fluorine-18 is a commonly used isotope utilized for conducting PSMA-PET/CT to stage prostate cancer, due to its longer half-life and higher production capacity as compared to Gallium-68. The latest study, however, has demonstrated superiority of Ga-68, because of the focal unspecific uptake of F-18 in the bones of ribs and pelvis. Without additional follow-up exams…

On Friday, 17 September 2021, Novartis announced further positive findings from the VISION trial: 177Lu-PSMA-617 therapy delays worsening of physical functioning and the onset of pain symptoms in patients with mCRPC. Hence, beyond extending overall survival and progress-free period, this Breakthrough Therapy also improves health-related quality of life. Read more

National Comprehensive Cancer Network, an alliance of cancer centers in the US, whose guidelines in oncology are applied to treating cancers, has added 68Ga-PSMA-PET imaging to its clinical practice guidelines for prostate cancer. Moreover, it recognized the high precision of this diagnostic tool as a primary stand-alone method and scrapped conventional imaging as a necessary…

Markus Hartenbach remporte le prix du jeune chercheur du conseil d’oncologie de l’association nord-américaine de médecine nucléaire

Équipe de chercheurs dirigée par Ass. Prof. Dr. Markus Hartenbach a pu démontrer la supériorité du TEP PSMA dans le diagnostic de la récidive biochimique du cancer de la prostate, même à de faibles niveaux de PSA. European Journal of Nuclear Medicine and Molecular Imaging

Équipe de chercheurs dirigée par Prof. Dr. Markus Hartenbach a pu démontrer la valeur diagnostique exceptionnelle du TEP/IRM PSMA dans le cancer de la prostate confirmé par biopsie.  

Frontiers in Urology

Video: Nuclear imaging 68Ga-DOTATATE and PRRT 177Lu-DOTATATE explained (English) NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT), Stanford, US, March 2017

New phase III 177Lu-PSMA-617 trial in mCRPC patients at the stage of antihormonal therapy

New phase III 177Lu-PSMA-617 trial in mCRPC patients who have not undergone chemotherapy.

ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

The New England Journal of Medicine: « Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer » 

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors Informationen zu Lutathera

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making

Alpha emitter radium-223 and survival in metastatic prostate cancer.  Les informations sur Xofigo

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study